Terns Pharmaceuticals (TERN) Operating Income: 2020-2024
Historic Operating Income for Terns Pharmaceuticals (TERN) over the last 5 years, with Dec 2024 value amounting to -$101.9 million.
- Terns Pharmaceuticals' Operating Income fell 21.26% to -$16.8 million in Q4 2022 from the same period last year, while for Dec 2022 it was -$62.0 million, marking a year-over-year decrease of 24.41%. This contributed to the annual value of -$101.9 million for FY2024, which is 0.67% up from last year.
- Per Terns Pharmaceuticals' latest filing, its Operating Income stood at -$101.9 million for FY2024, which was up 0.67% from -$102.6 million recorded in FY2023.
- Terns Pharmaceuticals' Operating Income's 5-year high stood at -$37.0 million during FY2020, with a 5-year trough of -$102.6 million in FY2023.
- Its 3-year average for Operating Income is -$88.8 million, with a median of -$101.9 million in 2024.
- As far as peak fluctuations go, Terns Pharmaceuticals' Operating Income tumbled by 65.34% in 2023, and later grew by 0.67% in 2024.
- Over the past 5 years, Terns Pharmaceuticals' Operating Income (Yearly) stood at -$37.0 million in 2020, then slumped by 34.67% to -$49.9 million in 2021, then dropped by 24.41% to -$62.0 million in 2022, then slumped by 65.34% to -$102.6 million in 2023, then grew by 0.67% to -$101.9 million in 2024.